company background image
DVAX logo

Dynavax Technologies NasdaqGS:DVAX Stock Report

Last Price

US$11.81

Market Cap

US$1.5b

7D

7.5%

1Y

-16.9%

Updated

29 Oct, 2024

Data

Company Financials +

Dynavax Technologies Corporation

NasdaqGS:DVAX Stock Report

Market Cap: US$1.5b

DVAX Stock Overview

A commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States.

DVAX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth4/6
Past Performance2/6
Financial Health4/6
Dividends0/6

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

US$24.60
FV
52.0% undervalued intrinsic discount
20.35%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
7 days ago author updated this narrative

Dynavax Technologies Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Dynavax Technologies
Historical stock prices
Current Share PriceUS$11.81
52 Week HighUS$15.15
52 Week LowUS$9.74
Beta1.37
11 Month Change7.36%
3 Month Change5.54%
1 Year Change-16.89%
33 Year Change-42.50%
5 Year Change120.34%
Change since IPO-87.44%

Recent News & Updates

Recent updates

Is Dynavax Technologies (NASDAQ:DVAX) Using Debt In A Risky Way?

Oct 12
Is Dynavax Technologies (NASDAQ:DVAX) Using Debt In A Risky Way?

Dynavax Technologies: Slow And Steady Wins The Race

Sep 05

Dynavax Technologies: A Two Trick Pony Operating With A Single Trick

Aug 23

Some May Be Optimistic About Dynavax Technologies' (NASDAQ:DVAX) Earnings

Aug 14
Some May Be Optimistic About Dynavax Technologies' (NASDAQ:DVAX) Earnings

Is Dynavax Technologies (NASDAQ:DVAX) Weighed On By Its Debt Load?

Jul 12
Is Dynavax Technologies (NASDAQ:DVAX) Weighed On By Its Debt Load?

Lacklustre Performance Is Driving Dynavax Technologies Corporation's (NASDAQ:DVAX) Low P/S

May 22
Lacklustre Performance Is Driving Dynavax Technologies Corporation's (NASDAQ:DVAX) Low P/S

Dynavax: HEPLISAV-B Growth Up, Pipeline Uncertain

May 10

Dynavax: Holding Firm Despite Its Missing Cash Cow

Mar 23

Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?

Mar 06
Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?

Dynavax Technologies Corporation's (NASDAQ:DVAX) Business And Shares Still Trailing The Industry

Jan 31
Dynavax Technologies Corporation's (NASDAQ:DVAX) Business And Shares Still Trailing The Industry

These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Safely

Aug 02
These 4 Measures Indicate That Dynavax Technologies (NASDAQ:DVAX) Is Using Debt Safely

Improved Earnings Required Before Dynavax Technologies Corporation (NASDAQ:DVAX) Shares Find Their Feet

Jun 02
Improved Earnings Required Before Dynavax Technologies Corporation (NASDAQ:DVAX) Shares Find Their Feet

We Think Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt With Ease

May 03
We Think Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt With Ease

Dynavax Technologies (NASDAQ:DVAX) Seems To Use Debt Rather Sparingly

Jan 16
Dynavax Technologies (NASDAQ:DVAX) Seems To Use Debt Rather Sparingly

Clover, Dynavax COVID-19 vaccine gets EU GMP certificate

Sep 20

Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?

Sep 12
Is Dynavax Technologies (NASDAQ:DVAX) A Risky Investment?

The Alphavaxers: Dynavax And Novavax, 2 Quarters On

Aug 22

Dynavax up 8% after raising full-year guidance for key adjuvant product, Q2 beats

Aug 04

Are Investors Undervaluing Dynavax Technologies Corporation (NASDAQ:DVAX) By 41%?

Jun 03
Are Investors Undervaluing Dynavax Technologies Corporation (NASDAQ:DVAX) By 41%?

Dynavax: Evolving Endemic Situation Adds To Its Risk

May 23

Dynavax Technologies' (NASDAQ:DVAX) Performance Is Even Better Than Its Earnings Suggest

May 12
Dynavax Technologies' (NASDAQ:DVAX) Performance Is Even Better Than Its Earnings Suggest

Dynavax Technologies (NASDAQ:DVAX) Could Easily Take On More Debt

May 10
Dynavax Technologies (NASDAQ:DVAX) Could Easily Take On More Debt

Dynavax Technologies: Full Speed Ahead

Mar 01

Here's Why Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt Responsibly

Jan 28
Here's Why Dynavax Technologies (NASDAQ:DVAX) Can Manage Its Debt Responsibly

Dynavax: A Coronavirus Growth Story

Jan 17

Is Dynavax Technologies Corporation (NASDAQ:DVAX) Expensive For A Reason? A Look At Its Intrinsic Value

Nov 18
Is Dynavax Technologies Corporation (NASDAQ:DVAX) Expensive For A Reason? A Look At Its Intrinsic Value

The Momentum Investor: Spotlight On Dynavax Technologies

Oct 25

Shareholder Returns

DVAXUS BiotechsUS Market
7D7.5%-0.2%-0.09%
1Y-16.9%27.0%38.6%

Return vs Industry: DVAX underperformed the US Biotechs industry which returned 28.6% over the past year.

Return vs Market: DVAX underperformed the US Market which returned 39.5% over the past year.

Price Volatility

Is DVAX's price volatile compared to industry and market?
DVAX volatility
DVAX Average Weekly Movement4.8%
Biotechs Industry Average Movement9.7%
Market Average Movement6.1%
10% most volatile stocks in US Market15.2%
10% least volatile stocks in US Market3.0%

Stable Share Price: DVAX has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: DVAX's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1996408Ryan Spencerwww.dynavax.com

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B.

Dynavax Technologies Corporation Fundamentals Summary

How do Dynavax Technologies's earnings and revenue compare to its market cap?
DVAX fundamental statistics
Market capUS$1.49b
Earnings (TTM)US$17.18m
Revenue (TTM)US$249.69m

90.1x

P/E Ratio

6.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
DVAX income statement (TTM)
RevenueUS$249.69m
Cost of RevenueUS$98.80m
Gross ProfitUS$150.90m
Other ExpensesUS$133.72m
EarningsUS$17.18m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

Nov 07, 2024

Earnings per share (EPS)0.13
Gross Margin60.43%
Net Profit Margin6.88%
Debt/Equity Ratio34.7%

How did DVAX perform over the long term?

See historical performance and comparison